Julius Clinical Announces Appointment of Bassem Saleh as CEO
Julius Clinical Welcomes New Leadership in Clinical Research
Julius Clinical, a prominent clinical Contract Research Organization (CRO), has announced that Bassem Saleh is now its Chief Executive Officer. Known for its expertise in central nervous system (CNS) and cardiometabolic diseases, the company sees Bassem’s experience as instrumental in achieving its growth objectives.
Bassem Saleh's Background and Experience
Bassem Saleh joins Julius Clinical with a wealth of experience from both larger and mid-sized clinical CROs. His previous role as CEO of TFS HealthScience allowed him to navigate extensive international expansion and spearhead various mergers and acquisitions. He possesses a proven track record in structuring operational teams tailored to specific therapeutic areas such as CNS, Dermatology, Ophthalmology, and Oncology, which aligns perfectly with Julius Clinical's growth strategy.
Bassem Saleh's Vision for Julius Clinical
Saleh expressed his enthusiasm for taking on this role, stating, "I am thrilled to be a part of Julius Clinical. The company has established a remarkable reputation for delivering high-quality and adaptable clinical trials in both biotech and pharma. As we move towards personalized treatments, the demand for specialized mid-sized CROs is increasing. I believe Julius Clinical's operational model, blending scientific expertise with strong customer partnerships, positions us well for leadership in this field.”
The Role of Daniel Spasic
Following this transition, Daniel Spasic, who has led the company as CEO since mid-2021, will shift to a position as Board Advisor. His guidance and foresight remain invaluable as Julius Clinical forges ahead under new leadership.
Overview of Julius Clinical's Operations
Operating across Europe and North America, Julius Clinical manages global Phase I–III clinical trials alongside real-world evidence studies focused on CNS, cardiometabolic, and rare diseases. The organization is distinguished for its scientific leadership and high-quality delivery processes while relying on a world-class network of sites and prominent opinion leaders.
Strengthening Partnerships and Expanding Influence
With the backing of Ampersand Capital Partners, Julius Clinical is focusing on enhancing its global presence. The firm is dedicated to bolstering trust and collaborative relationships with biotech and pharmaceutical companies worldwide, ensuring that innovative treatments are efficiently developed and brought to market.
About Julius Clinical
Founded in 2008, Julius Clinical specializes in central nervous system, cardio-metabolic, renal, and rare diseases, with over 400 clinical trials involving more than 300,000 subjects around the world. The combination of scientific leadership, operational excellence, and a global research network enables Julius Clinical to deliver bespoke solutions tailored to the needs of its clients in biotech and midsized pharma.
For more information about Julius Clinical, interested parties can contact:
Toni Kovandjieva Julius Clinical +31 30 656 9900 toni.kovandjieva@juliusclinical.com
Frequently Asked Questions
Who is the new CEO of Julius Clinical?
Bassem Saleh has been appointed the new Chief Executive Officer of Julius Clinical.
What experience does Bassem Saleh bring?
Bassem has extensive leadership experience in clinical CROs, having held the position of CEO at TFS HealthScience, where he oversaw significant growth and development.
What are Julius Clinical's specializations?
Julius Clinical specializes in CNS, cardiometabolic, renal, and rare diseases, managing various clinical trials.
What is Julius Clinical's operational model?
The company integrates deep scientific expertise with extensive site networks and strong customer relationships to lead in clinical trial solutions.
How does Julius Clinical plan to expand?
With support from Ampersand Capital Partners, Julius Clinical aims to broaden its global footprint and enhance partnerships with biotech and pharma companies.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
